XTX Topco’s Telomir Pharmaceuticals TELO Stock Holding History

XTX Topco’s Portfolio TELO Stock Details TELO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-36,061	Closed	-$46.9K	–	4801
2026 Q1	$46.9K	Sell	36,061 -3,651	-9%	-$4.66K	﹤0.01%	3339
2025 Q4	$52.8K	Buy	+39,712	New	+$57.3K	﹤0.01%	2816

Other funds holding TELO

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

WIA

World Investment Advisors Santa Barbara, California $6.04B AUM 22.7% 1-Year Est. Return

XTX Topco's TELO Position: Q2 2026 in Review

XTX Topco sold out of Telomir Pharmaceuticals (TELO) in Q2 2026, closing a stake of 36,061 shares — an estimated $46.9K sold.

XTX Topco first reported a position in TELO in Q4 2025 and held it in 2 quarters. The position peaked at $52.8K in Q4 2025. 33 funds tracked by Wall St. Rank hold TELO as of Q2 2026.

XTX Topco reported no remaining Telomir Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
XTX Topco sold 36,061 Telomir Pharmaceuticals shares in Q2 2026, an estimated $46.9K.
XTX Topco first reported a position in Telomir Pharmaceuticals in Q4 2025 and held it in 2 quarters.
XTX Topco's Telomir Pharmaceuticals position peaked at $52.8K in Q4 2025.
33 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.